Accumulate Strides Pharma Science; target of Rs 621: Geojit

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Geojit's research report on Strides Pharma Science

Strides saw its Q1FY21 revenues grow by 14% on a YoY basis and 26% sequentially to Rs.782cr on the back of revenue growth in the regulated markets The U.S business grew by 8% YoY (Excluding ranitidine sales) led by successful new launches and growth in market share of existing products Strides plans to launch 10+ new products in the regulated markets during FY21. The company stated that the US$40 million investment in Stelis Biopharma made last year is expected to break-even by FY22.

Outlook

We reiterate a "Accumulate" rating on the Strides based on 13x FY22E EPS with a target price of Rs.621

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More